DELINIA
Delinia was founded to discover and develop novel therapeutics for the treatment of autoimmune and inflammatory diseases. Delinia’s lead program is a molecule that selectively potentiates and expands regulatory T cells (Tregs), the powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Delinia’s scientific founders and experienced executive leaders are working to advance the company’s initial programs to the clinic.
DELINIA
Industry:
Biotechnology Medical Therapeutics
Founded:
2015-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.deliniabio.com
Total Employee:
11+
Status:
Closed
Contact:
708-555-1234
Email Addresses:
[email protected]
Total Funding:
35 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail ReCAPTCHA Microsoft Azure DNS Proofpoint CSC Global DNS
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
NFlection Therapeutics
NFlection focuses on the development of novel therapies to address the needs of patients.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Current Advisors List
Founder
Investors List
Sofinnova Partners
Sofinnova Partners investment in Series A - Delinia
Atlas Venture
Atlas Venture investment in Series A - Delinia
Official Site Inspections
http://www.deliniabio.com
- Host name: 165.160.13.20
- IP address: 165.160.13.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Delinia"
Delinia - Crunchbase Company Profile & Funding
Delinia was founded to discover and develop novel therapeutics for the treatment of autoimmune and inflammatory diseases.See details»
Delinia 2025 Company Profile: Valuation, Investors, …
Information on acquisition, funding, cap tables, investors, and executives for Delinia. Use the PitchBook Platform to explore the full profile.See details»
Sofinnova Partners announces the acquisition of Delinia by …
Jan 26, 2017 Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings …See details»
Delinia Company Profile | Management and Employees List
Find contact information for Delinia. Learn about their Research & Development, Business Services market share, competitors, and Delinia's email format.See details»
Delinia - 2025 Company Profile, Funding & Competitors - Tracxn
Delinia - Developing regulatory T cell based small molecule therapeutics for autoimmune diseases. Acquired by Celgene. Raised a total funding of $35M over 1 round from 2 investors.See details»
Delinia - Overview, News & Similar companies | ZoomInfo.com
View Delinia (www.deliniabio.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Delinia - VentureRadar
Delinia was founded to discover and develop novel therapeutics for the treatment of autoimmune and inflammatory diseases. Delinia's lead program is a molecule that selectively potentiates …See details»
Delinia Overview | SignalHire Company Profile
Delinia is a private company that has been in the industry for 7 years. The company currently specializes in the Biotechnology, Health Care Technology areas. The position of the President …See details»
Delinia - LinkedIn
About us Delinia is a biotechnology company developing novel therapeutics for the treatment of serious autoimmune diseases. Delinia's lead program is a molecule that potentiates and …See details»
Delinia, Inc.:Company Profile & Technical Research,Competitor …
Discovery Company profile page for Delinia, Inc. including technical research,competitor monitor,market trends,company profile& stock symbolSee details»
Delinia’s Competitors, Revenue, Number of Employees, Funding
Delinia’s Profile, Revenue and Employees. Delinia is a biotechnology company that develops novel therapeutics for the treatment of autoimmune and inflammatory diseases. Delinia’s …See details»
Articles about Delinia, Inc. - BioSpace
Delinia’s scientific founders and experienced executive leaders are working to advance the company’s initial programs to the clinic. Delinia is headquartered in Cambridge, …See details»
Delinia Inc. - [LSE] Life-Sciences-Europe.com - The European Life ...
Delinia is a biotechnology company developing novel therapeutics for the treatment of autoimmune diseases. Delinia's lead program DEL106 is an IL-2 mutein Fc fusion protein …See details»
Delinia, Inc. | Insights
Dec 20, 2017 Latest on Delinia, Inc. Already A Biomedtracker Subscriber?You have access to the full company record through your subscription.See details»
Delinia Announces $35 Million Series A Financing to Advance …
Sep 14, 2016 The Company Will Develop New Medicines to Selectively Potentiate and Expand Regulatory T Cells CAMBRIDGE, MA. and SAN FRANCISCO, CA. September 14, 2016 – …See details»
Delinia - Wiki | Golden
Delinia is creating novel therapeutics that rebalance the immune system for treating serious and life-threatening autoimmune diseases. Delinia has a novel protein therapeutic platform that is …See details»
Delinia - Products, Competitors, Financials, Employees, …
About Delinia Delinia was founded to discover and develop novel therapeutics for the treatment of autoimmune and inflammatory diseases. Delinia's lead program is a molecule that selectively …See details»
Celgene Bangs Out Deal Worth $775 Million for Kendall Square …
Jan 26, 2017 Summit, NJ-based Celgene Corporationannounced today that it was acquiring Cambridge, Mass.-based Delinia for $300 million upfront and an additional $475 million in …See details»
Celgene splashes out $300M on Delinia autoimmune biotech buy
Jan 26, 2017 As Johnson & Johnson announced its $30 billion for Actelion this morning, Celgene is also jumping on the M&A bandwagon with a $775 million biobucks deal for Delinia, …See details»
Smart contours: deep learning-driven internal gross tumor volume ...
1 day ago Background Delineating the internal gross tumor volume (IGTV) is crucial for the treatment of non-small cell lung cancer (NSCLC). Deep learning (DL) enables the automation …See details»